Meeting annuel 2016 – Paris
Suite au succès d’ENM 2015, SFNano organise son 3e congrès annuel à Paris
Suite au succès d’ENM 2015, SFNano organise son 3e congrès annuel à Paris
|Conception et caractérisation de NanosystèmesMots clefs : Nanovecteurs, nano-dispositifs médicaux, méthodes d’obtention, méthodes de caractérisation|
|Nanomédecine & délivrance de macromoléculesMots clefs : Acides nucléiques, protéines, délivrance de peptides, potentialisation ou activation du système immunitaire, ciblage de cellules du système immunitaire|
|Nanomédecine & CancerMots clefs : Nanosystèmes (nanoparticules, macromolécules..) pour le traitement de tumeurs, nanosystèmes ciblés, assemblages nanomoléculaires avec délivrance activée par divers stimuli|
|Nanomédecine & Imagerie médicaleMots clefs : Nanosystèmes (nanoparticules, macromolécules..) pour détecter, diagnostiquer ou délivrer des molécules. Thérapie guidée par l’imagerie|
|Nanomédecine & Infections sévèresMots clefs : Nanosystèmes (nanoparticules, macromolécules..) pour détecter, diagnostiquer ou traiter des maladies infectieuses.|
Vous trouverez ci-dessous notre sélection de conférenciers internationaux de renom. Les titres provisoires des conférences sont disponibles et leurs résumés seront publiés peu avant le congrès.
Mark Grinstaff, Ph.D.
Professor of Chemistry and Biomedical Engineering
Boston University – Boston (USA)
« Expansile Nanoparticles for the Treatment of Intraperitoneal Mesothelioma »
Mark W. Grinstaff is the Distinguished Professor of Translational Research and a Professor of Biomedical Engineering, Chemistry, Materials Science and Engineering, and Medicine as well as the Director of the NIH T32 Program in Biomaterials at Boston University. Mark’s awards include the ACS Nobel Laureate Signature Award, NSF Career Award, Pew Scholar in the Biomedical Sciences, Camille Dreyfus Teacher-Scholar, Alfred P. Sloan Research Fellowship, the Edward M. Kennedy Award for Health Care Innovation, and a Founding Fellow of the National Academy of Inventors. Over the course of his tenure, Grinstaff’s groundbreaking research has yielded more than 250 peer-reviewed publications, more than 200 patents and patent applications, and more than 300 oral presentations. His students and postdoctoral fellows have given more than 400 poster and 150 oral presentations at national and international conferences. His H index is 60’s, and his work has been cited more than 16,500 times. He is a co-founder of five companies and his innovative ideas and his efforts have also led to one new FDA approved pharmaceutical (AbraxaneTM) and four medical device products (OcuSeal® and Adherus Surgical Sealants®) that improve clinical care for hundreds of thousands of people. His current research activities involve the synthesis of new macromolecules and biomaterials, self-assembly chemistry, imaging contrast agents, drug delivery, and wound repair.
Iraida Loinaz, Ph.D.
Nanomedicine Business Development Manager
Fundación CIDETEC – Donostia – San Sebastián (Spain)
« NanoPilot: A pilot plant operating under GMP for nanopharmaceuticals manufacturing »
Iraida Loinaz is the Nanomedicine Business Developer Manager of CIDETEC. She was specialized in Organic Chemistry and her PhD thesis was focused on peptidic synthesis and synthesis in perfluorocarbon media. In 2004 she moved to Fundación CIDETEC. In 2005 she became the Head of Biomaterials Unit in CIDETEC. The main research activities of the Unit have been focused from the beginning in the synthesis and characterization of biomaterials and bioactive surfaces. She is co-inventor of 5 patents and published more than 30 scientific papers. She has strong background in the synthesis of polymer nanoparticles, nanogels and hydrogels, with special attention in the synthesis of single-chain polymer nanoparticles with application in drug-delivery and imaging. In the field of bioactive surfaces, they actively work in the generation of highly hydrophilic coatings to reduce the wear and friction in prosthesis, or controlling the biofouling. In the last years the group has been specialized in translational research and they are establishing a pilot plant operating under GMP for the production of nanopharmaceuticals.
Laurent Cognet, Ph.D.
Centre National de la Recherche Scientifique – Talence (France)
« Nanoscale imaging of live brain tissue »
Laurent Cognet is Research Director at CNRS and is a member of the Laboratoire Photonique Numérique et Nanosciences(LP2N), a joint research unit of Institut d’Optique Graduate School, CNRS & University of Bordeaux, France. After a PhD in atom optics at Institut d’Optique-Orsay supervised by A. Aspect (Paris Sud University) L. Cognet performed among the first experiments about the detection and tracking of single fluorescent molecules in living cells as a postdoc in Th. Schmidt’s group at Leiden University (NL). In 2000, he was tenured by CNRS as junior researcher at University of Bordeaux and he was promoted Research Director in 2009. In 2006, he spent a one-year sabbatical leave as a Fulbright scholar at Rice University (Houston, Texas) to work on carbon nanotube imaging. In 2011, he participated in the creation of LP2N where is deputy director and coordinates the Optics and Biology Research Initiative. His research interests include single molecule detection, super-resolution microscopy, single-wall carbon nanotube optics, and high-resolution bio-imaging applications with a particular focus in neuroscience.
Patrick Couvreur, Prof.
Faculté de Pharmacie, Université Paris Sud – Chatenay-Malabry (France)
« Nanomedicines for the treatment of severe diseases »
Patrick COUVREUR is Full Professor of Pharmacy at Paris-Sud University and holder of the chair “Innovation Technologique” (2009-2010) at the prestigious « Collège de France ». He is appointed as a Senior Member of the “Institut Universitaire de France” since 2009. He is the recipient of an “ERC Advanced Grant” (2010-2015) and of an “ERC Proof of Concept” (2015-2016). He has hold many important national and international academic positions as Director of the UMR CNRS 8612, Director of the Doctoral School “Therapeutic Innovation”, Founder member of the pole of competitivity MEDICEN, Extraordinary Professor at the University of Louvain (Belgium), member of the board of governors of many international scientific organizations.
His contributions to the field of drug delivery, nanomedicine and drug targeting are highly recognized around the world with more than 500 peer review research publications (Google Scholar H-index 118 and Thomson Reuters H-index 86), some of them in prestigious journals such as Nature Nanotechnol., Nature Mat., Nature Commun., Proceedings of the National Academy of Sciences, Angewandte Chemie, Cancer Research, or Journal of the American Chemical Society. His research is interdisciplinary, aiming at developping new nanomedicines for the treatment of severe diseases. This research is at the interface between Physico-Chemistry of Colloids, Polymer Chemistry, Material Science, Cellular and Molecular Biology and Experimental Pharmacology.
Patrick COUVREUR’s research has led to the funding of two start-up companies (Bioalliance and Medsqual). Bioalliance (now ONXEO) entered the stock market in 2005 and a nanomedicine invented in Couvreur’s lab is currently finishing phase III clinical trial for the treatment of hepatocarcinoma.
The major scientific contribution of Patrick COUVREUR to the Pharmaceutical Sciences has been recognized by numerous international and national awards, and by his appointment as a member of eight different academies.
Teresa Pellegrino, PhD
Istituto Italiano di Tecnologia – Genoa (Italy)
« Inorganic nanocrystals and their assemblies to tackle cancer and neuron diseases »
Teresa Pellegrino since 2014 is tenured team leader of the group of “Nanomaterials for Biomedical Applications” at the Italian Institute of Technology, Genoa, Italy. She received her PhD in Chemical synthesis in 2005 from the University of Bari. Her current research interests focus on the development of inorganic nanostructures for drug delivery, magnetic hyperthermia, photo-thermal treatment and radiotherapy applications.
Jan van Hest, Prof. Dr. Ir.
Technische Universiteit Eindhoven – Eindhoven (Netherlands)
« Designer compartments for nanomedicine »
Jan van Hest obtained his PhD from Eindhoven University of Technology in 1996 in macro-organic chemistry with prof E.W. Meijer. He worked as a postdoc with prof D.A. Tirrell on protein engineering. In 1997 he joined the chemical company DSM in the Netherlands. In 2000 he was appointed full professor in Bio-organic chemistry at Radboud University Nijmegen. As of September 2016 he holds the chair of Bio-organic Chemistry at Eindhoven University of Technology. The group’s focus is to develop well-defined compartments for nanomedicine and artificial cell research. Using a combination of techniques from polymer science to protein engineering, well-defined carriers and scaffolds are developed for application in e.g. cancer treatment, immunology and ophthalmology.
Van Hest was elected member of the “Jonge Akademie”, (The Young Academy of the Royal Netherlands Academy of Arts and Sciences) in 2005. He has won a TOP grant (2007) and a VICI grant (2010), the highest personal career grant obtainable through open competition in the Netherlands. In 2012 he was one of the main applicants of the 10-year gravitation program on functional molecular systems (26.9 M€, with the universities of Eindhoven, Groningen and Nijmegen). In 2016 he was awarded an ERC Advanced grant, and currently also coordinates the Horizon 2020 ITN Network Nanomed, dedicated to developing smart delivery carriers in medicine. Van Hest is associate editor of Bioconjugate Chemistry. He is furthermore an advisory board member of Macromolecular Bioscience, Biomacromolecules, Journal of Materials Chemistry, Chemical Science and ACS Central Science. He has been elected Fellow of the Royal Society of Chemistry of the UK.
32 PhD students have obtained their doctorate degree under his supervision, and he currently supervises 18 PhD students. He has published more than 290 papers (H factor 55). He is also cofounder of four start-up companies (Encapson, FutureChemistry, Noviosense and Noviotech).
Guy Kantor, MD PhD
Institut Bergonié – Bordeaux (France)
« Radio enhancement with nanoparticules. First human clinical trials. »
Guy kantor Is professor of cancerology at the University of Bordeaux and radiation Oncologist at the Institut Bergonié , comprehensive cancer centre of Bordeaux . His research includes clinical research ( mainly in the field of sarcoma and brain tumors) and technological developpments (in the field of imaging and radiation therapy).
Radiation enhancement with high Z number metal nanoparticules is a promising hypothesis for radiation therapy of tumors. He participed as principal investigator, to the First in human (FIH) trial with intra tumoral use of hafnium radioparticules in sarcomas. He his also implicated for evaluation of use of gadolinium after irradiation of brain metatstases.
He coordinates an interface program POPRA, “ programme Optique Physique et Radiothérapie en Aquitaine » supported by the région Nouvelle-Aquitaine to facilitate collaborations between clinicians such as radiation oncologists and medical physicists and fundamental research actors in the field of physics, mathematics, informatics and biology. In this program, radiation enhancement,mechanisms of antitumoral actions of nanoparticles is perfomed in a close collaboration with CENBG ( iribio group , Dr Seznec, CNRS). He is also coordinator of the regional network “ Canceropôle grand sud ouest “ for the axis Health and technology.
Kazunori Kataoka, Ph.D.
Kawasaki Institute of Industrial Promotion – Kawasaki (Japan)
« Self-Assembled Supramolecular Nanosystems for Smart Diagnosis and Targeted Therapy of Intractable Diseases »
Dr. Kazunori Kataoka is Director General of Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industry Promotion. He is also Professor at Policy Alternatives Research Institute, The University of Tokyo.
He received his B.Eng. (1974) in Organic Chemistry, M.Eng. (1976) and Ph.D. (1979) in Polymer Chemistry from The University of Tokyo. He started his academic career at Institute of Biomedical Engineering, Tokyo Women’s Medical College as Assistant Professor (1979) and was promoted to Associate Professor in 1988. He moved to Department of Materials Engineering, Tokyo University of Science in 1989 as Associate Professor and was promoted to full Professor in 1994. He joined Department of Materials Engineering, The University of Tokyo in 1998 as full Professor. He was appointed joint-position of full Professor at Center for Disease Biology and Integrative Medicine, The University of Toyo Medical School in 2004. In 2016, he took mandatory retirement from Graduate School of Engineering/Graduate School of Medicine, The University of Tokyo, and moved to the current position. He has been appointed as Adjunct Professor at Eshelman School of Pharmacy, University of North Carolina Chapel Hill since 2015.
He has received several scientific awards, including the Clemson Award from the Society for Biomaterials, USA (2005), the Founder’s Award from the Controlled Release Society (2008), Humboldt Research Award from Alexander von Humboldt Foundation (2012), and Leo Esaki Prize (2012). He has been elected as a Foreign Member of the US National Academy of Engineering (NAE) since 2017. His current major research interests include supramolecular materials for nanobiotechnology, focusing on drug and gene delivery systems.
Jinjun Shi, PhD
Assistant Professor of Anaesthesia
Brigham and Women’s Hospital – Boston (USA)
« Nanomedicine for Cancer and Ischemic Brain Damage »
Dr. Jinjun Shi is an Assistant Professor at Harvard Medical School and a faculty member in the Center for Nanomedicine at Brigham and Women’s Hospital. He has developed various nanotechnologies for drug delivery and medical applications. The immuno-nanotherapeutic technologies developed by him and his colleagues are in clinical trials for treatment of inflammatory diseases. He has published over 40 peer-reviewed papers and holds more than 35 patents/patent applications worldwide. His laboratory is currently developing innovative biomaterials and nanotechnologies for biomedical research and applications.
Wim E. Hennink, Prof. Dr. ir.
Head of Department
Utrecht University – Utrecht (Netherlands)
« Nanogels for the intracellular delivery of proteins for cancer treatment »
Wim Hennink obtained his Ph.D. degree in 1985 at the Twente University of Technology on a thesis with a biomaterials research topic. From 1985 until 1992 he had different positions in the industry. In 1992 he was appointed as professor at the Faculty of Pharmacy of the University of Utrecht. From 1996 on he is head of the Pharmaceutics division. At present he is the head of the Department of Pharmaceutical Sciences, Utrecht University. His main research interests are in the field of polymeric drug delivery systems. He published over 450 papers and book chapters and is the inventor of 20 patents.
Joël RICHARD, PhD
Senior Vice President, Peptides Development
IPSEN – Dreux (France)
« Peptide delivery : how can nanosystems help address present and future challenges »
Dr Joël Richard is currently Senior Vice President, Peptides Development in IPSEN (France). He is globally leading all the IPSEN pharmaceutical development activities of small molecules and peptide-based products, including APIs and drug products, with major franchises in Oncology, Endocrinologie and Neurology. Dr Richard has more than 28 years of experience in chemistry and biopharmaceutical R&D, including several global senior positions in various Biotech and Pharma companies, such as:
– Vice President, Drug Product Development in IPSEN (France) (2008-2011),
– Director, Pharmaceutical Development in Serono and Merck Serono (Italy, Germany) (2005-2008),
– Vice President Research, and Europe R&D Director at Ethypharm (France) (2001-2004),
– COO at Mainelab (France), a drug delivery company he co-founded with Jean-Pierre Benoit, which was specialized in developing solvent-free processes for protein delivery systems (1999-2004).
Since 1996, Dr Richard has focused his research activity on new formulation technologies and drug delivery systems (such as microspheres, nanoparticles, nanocapsules, chemically-modified proteins, supercritical fluid technology . . .), especially for injectable peptide and protein formulations. Dr Richard graduated from Ecole Normale Supérieure (Cachan, 1985). He has got a PhD in Materials Science (University of Paris VI, 1987) and “Habilitation à Diriger les Recherches” in Chemistry (University of Bordeaux I, 1993). He has published 67 peer-reviewed scientific papers, 8 book chapters and 2 review editorials in various fields (colloids and interfaces, drug delivery, supercritical fluids, protein formulations, nanoparticles, sustained-release formulations). He is the author of more than 130 international communications and 53 patent families.
Voici le programme du congrès annuel. Il comprend les conférences qui seront données par les conférenciers invités ainsi que les communications orales sélectionnées par le comité scientifique à partir des abstracts qui ont été soumis.
En cliquant sur l’image ci-dessous, ou ici, vous pourrez visualiser la dernière version de ce programme.
Voici également la liste des sponsors de notre dernier événement, ENM 2015. Voyez pourquoi il est intéressant de sponsoriser cet événement : choisissez votre pack !